Cetera Investment Advisers Has $601,000 Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Cetera Investment Advisers raised its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 19.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,109 shares of the company’s stock after purchasing an additional 1,160 shares during the period. Cetera Investment Advisers’ holdings in Axsome Therapeutics were worth $601,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Brevan Howard Capital Management LP increased its stake in Axsome Therapeutics by 169.9% during the 4th quarter. Brevan Howard Capital Management LP now owns 38,748 shares of the company’s stock worth $3,278,000 after acquiring an additional 24,393 shares during the period. Bridgefront Capital LLC acquired a new stake in shares of Axsome Therapeutics during the 4th quarter worth $893,000. BVF Inc. IL increased its position in shares of Axsome Therapeutics by 32.7% in the fourth quarter. BVF Inc. IL now owns 1,388,064 shares of the company’s stock worth $117,444,000 after purchasing an additional 342,064 shares during the period. Balyasny Asset Management L.P. increased its position in shares of Axsome Therapeutics by 171.0% in the fourth quarter. Balyasny Asset Management L.P. now owns 181,213 shares of the company’s stock worth $15,332,000 after purchasing an additional 114,346 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in Axsome Therapeutics by 1,251.9% in the fourth quarter. BNP Paribas Financial Markets now owns 185,661 shares of the company’s stock valued at $15,709,000 after purchasing an additional 171,928 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Insiders Place Their Bets

In other news, Director Mark Coleman sold 3,000 shares of Axsome Therapeutics stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $107.49, for a total transaction of $322,470.00. Following the sale, the director now directly owns 54,137 shares of the company’s stock, valued at approximately $5,819,186.13. This trade represents a 5.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 22.30% of the company’s stock.

Axsome Therapeutics Stock Performance

Shares of Axsome Therapeutics stock opened at $105.07 on Tuesday. The company’s 50 day moving average price is $108.44 and its two-hundred day moving average price is $106.00. The firm has a market capitalization of $5.17 billion, a P/E ratio of -17.54 and a beta of 0.46. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $139.13. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04.

Analysts Set New Price Targets

AXSM has been the topic of a number of analyst reports. William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Mizuho boosted their target price on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the company an “outperform” rating in a research report on Thursday, March 27th. Needham & Company LLC reiterated a “buy” rating and set a $153.00 price target on shares of Axsome Therapeutics in a research report on Tuesday, April 1st. Leerink Partners lifted their price objective on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday, February 10th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Axsome Therapeutics in a research report on Tuesday, February 11th. They set a “buy” rating and a $176.00 price objective for the company. One analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $172.14.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.